Welcome to our website.
If you would like to invest in Sementis please contact us.
- Zika press
- AGM - 25th Nov 2016
An immune modulation therapy designed to cure peanut allergy
A vaccine for the highly infectious Chikungunya Virus
Proprietary viral vector delivery vehicle
An immune modulating therapy designed to cure cat allergy
Our pipeline of products are all based upon the proprietary SCV Vector System enabling solutions for the treatment of allergies and infectious disease. All products are designed to harness the patient’s own immune system in fighting disease.
The proprietary SCV system is a novel live non-replicating antigen delivery technology that enables the development of new vaccines in the field infectious diseases, allergies and oncology.
Consists of experienced corporate professionals from the financial, pharmaceutical and biotechnology industries.